276 related articles for article (PubMed ID: 17223741)
1. Zoledronic acid in the management of metastatic bone disease.
Santini D; Fratto ME; Vincenzi B; Galluzzo S; Tonini G
Expert Opin Biol Ther; 2006 Dec; 6(12):1333-48. PubMed ID: 17223741
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer.
Lipton A
Clin Breast Cancer; 2007 Jul; 7 Suppl 1():S14-20. PubMed ID: 17683649
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid: past, present and future roles in cancer treatment.
Saad F
Future Oncol; 2005 Apr; 1(2):149-59. PubMed ID: 16555985
[TBL] [Abstract][Full Text] [Related]
4. New developments of aminobisphosphonates: the double face of Janus.
Santini D; Galluzzo S; Vincenzi B; Schiavon G; Fratto E; Pantano F; Tonini G
Ann Oncol; 2007 Jun; 18 Suppl 6():vi164-7. PubMed ID: 17591815
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
Dhillon S; Lyseng-Williamson KA
Drugs; 2008; 68(4):507-34. PubMed ID: 18318568
[TBL] [Abstract][Full Text] [Related]
6. The role of bisphosphonates in breast and prostate cancers.
Brown JE; Neville-Webbe H; Coleman RE
Endocr Relat Cancer; 2004 Jun; 11(2):207-24. PubMed ID: 15163299
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
8. Management of bone metastases in prostate cancer: a review.
Bienz M; Saad F
Curr Opin Support Palliat Care; 2015 Sep; 9(3):261-7. PubMed ID: 26262831
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates and breast cancer incidence and recurrence.
Chlebowski RT; Col N
Breast Dis; 2011; 33(2):93-101. PubMed ID: 22142660
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates in lung cancer: can they provide benefits beyond prevention of skeletal morbidity?
Hirsh V
Anticancer Agents Med Chem; 2012 Feb; 12(2):137-43. PubMed ID: 21864233
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid in the treatment of metastatic breast cancer.
Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
[TBL] [Abstract][Full Text] [Related]
12. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature.
Gnant M; Clézardin P
Cancer Treat Rev; 2012 Aug; 38(5):407-15. PubMed ID: 21983264
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
Hadji P; Coleman RE; Wilson C; Powles TJ; Clézardin P; Aapro M; Costa L; Body JJ; Markopoulos C; Santini D; Diel I; Di Leo A; Cameron D; Dodwell D; Smith I; Gnant M; Gray R; Harbeck N; Thurlimann B; Untch M; Cortes J; Martin M; Albert US; Conte PF; Ejlertsen B; Bergh J; Kaufmann M; Holen I
Ann Oncol; 2016 Mar; 27(3):379-90. PubMed ID: 26681681
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates for malignancy-related bone disease: current status, future developments.
Body JJ
Support Care Cancer; 2006 May; 14(5):408-18. PubMed ID: 16450087
[TBL] [Abstract][Full Text] [Related]
15. Anticancer activity of bisphosphonates in breast cancer.
Gnant M
Anticancer Agents Med Chem; 2012 Feb; 12(2):114-22. PubMed ID: 21864231
[TBL] [Abstract][Full Text] [Related]
16. New therapeutic agents for the treatment of bone diseases.
Lipton A
Expert Opin Biol Ther; 2005 Jun; 5(6):817-32. PubMed ID: 15952912
[TBL] [Abstract][Full Text] [Related]
17. Treatment of bone metastases in lung cancer: the actual role of zoledronic acid.
Ricciardi S; de Marinis F
Rev Recent Clin Trials; 2009 Sep; 4(3):205-11. PubMed ID: 20028333
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
[TBL] [Abstract][Full Text] [Related]
19. Optimal management of metastatic bone disease.
Major P
Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
[TBL] [Abstract][Full Text] [Related]
20. Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting.
Santini D; Virzi V; Fratto ME; Bertoldo F; Sabbatini R; Berardi R; Calipari N; Ottaviani D; Ibrahim T
Curr Cancer Drug Targets; 2010 Feb; 10(1):46-54. PubMed ID: 20088792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]